These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8700542)

  • 21. Changes in telomere lengths in renal cell carcinomas.
    Dahse R; Fiedler W; Ernst G; Kosmehl H; Schlichter A; Schubert J; Claussen U
    Cell Mol Biol (Noisy-le-grand); 1996 Jun; 42(4):477-85. PubMed ID: 8828903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Telomeres, telomerase and development of cancer].
    Andersen TI
    Tidsskr Nor Laegeforen; 1998 May; 118(13):2043-6. PubMed ID: 9656791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telomere maintenance in Wilms tumors: first evidence for the presence of alternative lengthening of telomeres mechanism.
    Venturini L; Daidone MG; Motta R; Collini P; Spreafico F; Terenziani M; Piva L; Radice P; Perotti D; Zaffaroni N
    Genes Chromosomes Cancer; 2011 Oct; 50(10):823-9. PubMed ID: 21769957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of telomerase activity and telomere length in bone and soft tissue tumors.
    Terasaki T; Kyo S; Takakura M; Maida Y; Tsuchiya H; Tomita K; Inoue M
    Oncol Rep; 2004 Jun; 11(6):1307-11. PubMed ID: 15138570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic determination of telomerase activity and telomerase length during the progression of human breast cancer in cell culture models.
    Imam SA; Kim MS; Anker L; Datar RH; Law RE; Taylor CR
    Anticancer Res; 1997; 17(6D):4435-41. PubMed ID: 9494546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical usefulness of telomerase activation and telomere length in head and neck cancer.
    Patel MM; Parekh LJ; Jha FP; Sainger RN; Patel JB; Patel DD; Shah PM; Patel PS
    Head Neck; 2002 Dec; 24(12):1060-7. PubMed ID: 12454944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues.
    Fan Y; Liu Z; Fang X; Ge Z; Ge N; Jia Y; Sun P; Lou F; Björkholm M; Gruber A; Ekman P; Xu D
    Clin Cancer Res; 2005 Jun; 11(12):4331-7. PubMed ID: 15958614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telomeres, telomerase and cancer: is the magic bullet real?
    Sharma HW; Maltese JY; Zhu X; Kaiser HE; Narayanan R
    Anticancer Res; 1996; 16(1):511-5. PubMed ID: 8615664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma.
    Engelhardt M; Albanell J; Drullinsky P; Han W; Guillem J; Scher HI; Reuter V; Moore MA
    Clin Cancer Res; 1997 Oct; 3(10):1849-57. PubMed ID: 9815573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telomeres, telomerase and chromosome stability.
    Preston RJ
    Radiat Res; 1997 May; 147(5):529-34. PubMed ID: 9146697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
    Tárkányi I; Aradi J
    Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternative lengthening of telomeres in mammalian cells.
    Henson JD; Neumann AA; Yeager TR; Reddel RR
    Oncogene; 2002 Jan; 21(4):598-610. PubMed ID: 11850785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telomere length, telomerase activity and telomerase RNA expression in human esophageal cancer cells: correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs.
    Asai A; Kiyozuka Y; Yoshida R; Fujii T; Hioki K; Tsubura A
    Anticancer Res; 1998; 18(3A):1465-72. PubMed ID: 9673357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telomerase reverse transcriptase and telomeric-repeat binding factor protein 1 as regulators of telomerase activity in pancreatic cancer cells.
    Yajima T; Yagihashi A; Kameshima H; Kobayashi D; Hirata K; Watanabe N
    Br J Cancer; 2001 Sep; 85(5):752-7. PubMed ID: 11531263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of primary renal carcinoma cultures.
    Sievers E; Dreimuller P; Haferkamp A; Schmidt-Wolf IG; Buchler MW; Schmidt J; Marten A
    Urol Int; 2007; 79(3):235-43. PubMed ID: 17940356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telomerase activity and telomere detection during early bovine development.
    Betts DH; King WA
    Dev Genet; 1999; 25(4):397-403. PubMed ID: 10570471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids.
    Perrem K; Bryan TM; Englezou A; Hackl T; Moy EL; Reddel RR
    Oncogene; 1999 Jun; 18(22):3383-90. PubMed ID: 10362359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN).
    Koeneman KS; Pan CX; Jin JK; Pyle JM; Flanigan RC; Shankey TV; Diaz MO
    J Urol; 1998 Oct; 160(4):1533-9. PubMed ID: 9751408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immortalized cells with no detectable telomerase activity. A review.
    Reddel RR; Bryan TM; Murnane JP
    Biochemistry (Mosc); 1997 Nov; 62(11):1254-62. PubMed ID: 9467849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telomerase activity in vivo in human malignant hematopoietic cells.
    Nilsson P; Mehle C; Remes K; Roos G
    Oncogene; 1994 Oct; 9(10):3043-8. PubMed ID: 8084612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.